IL6 and lung carcinoma: Potential upstream activators of STAT3 in lung cancer include IL-6, which has been reported to be constitutively produced in some lung cancer cell lines and lung cancer patients (20, 21), and EGFR, which is often overexpressed or mutated in the kinase domain in NSCLC cells (19).